Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, has appointed Julia Kirshner, PhD, as its new chief scientific officer. Kirshner has been serving as POAI’s senior vice president as well as president of the company’s zPREDICTA division, a company that she originally founded in 2014 and that POAI acquired. Kirshner’s appointment as CFO will begin Aug. 1, 2022. In this newly created role, Kirshner will manage the scientific process for Predictive Oncology’s entire suite of oncology drug-development solutions, from early discovery to clinical trials. She will oversee the company’s long-term vision for product development strategy, drive adoption of current POAI assets and guiding product iteration, and work the board of directors to establish a new scientific advisory board. In addition, Kirshner will facilitate the consolidation of POAI’s TumorGenesis division, which includes moving the operations to the company’s Pittsburgh location where POAI conducts its AI and lab functions. The company is working to consolidate and grow its research and development capabilities in order to better serve pharmaceutical and biotech companies looking to bring more effective cancer treatments to market. “Dr. Kirshner is a highly-qualified and well-respected scientific leader who understands the core technical and commercial value of each of the company’s product lines,” said Predictive Oncology CEO J. Melville Engle in the press release. “She brings the scientific experience and deep level of expertise to our product development process that makes her the ideal candidate to help guide, support and grow all our business units.”

To view the full press release, visit https://ibn.fm/l21w7

About Predictive Oncology Inc.

Predictive Oncology s a knowledge-driven company focused on applying artificial intelligence (AI) to develop optimal cancer therapies, which can lead to more effective treatments and improved patient outcomes. Through AI, Predictive Oncology uses a database of 150,000+ cancer tumors, categorized by patient type, against drug compounds to help the drug discovery process and increase the probability of success. The company offers a suite of solutions for oncology drug development from early discovery to clinical trials. For more information about the company, please visit www.Predictive-Oncology.com.

NOTE TO INVESTORS: The latest news and updates relating to POAI are available in the company’s newsroom at http://ibn.fm/POAI

About InvestorWire

InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent.

As part of its service, InvestorWire provides coverage of noteworthy announcements. To further expand visibility of achievements being made throughout a multitude of sectors, InvestorWire’s syndication partners have extended the digital coverage to include individual broadcasts on financial websites and platforms visited by millions of investors daily.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer

InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
Editor@InvestorWire.com

InvestorWire is part of the InvestorBrandNetwork.